Table 1.
Characteristics of subjects by randomization group at baseline.
| Variable | Total Sample (n = 56) | Placebo (n = 27) | VitD3 Supplementation (n = 29) |
|---|---|---|---|
| Age, (y) | 20.7±3.8 | 20.0±4.1 | 21.4±3.3 |
| Sex, male, n (%) | 38 (67%) | 18 (67%) | 20 (69%) |
| Racial identification, n (%) | |||
| African-American | 48 (86%) | 23 (86%) | 25 (86%) |
| White | 2 (3%) | 2 (7%) | 0 (0%) |
| Other and mixed | 6 (11%) | 2 (7%) | 4 (14%) |
| Season at enrollment, n (%) | |||
| Summer/Fall | 19 (34%) | 8 (30%) | 11 (38%) |
| Winters/Spring | 37 (66%) | 19 (70%) | 18 (62%) |
| HIV acquisition route, n (%) | |||
| Perinatally | 19 (34%) | 10 (37%) | 9 (31%) |
| Behaviorally | 37 (66%) | 17 (63%) | 20 (69%) |
| cART at baseline, n (%) | 42 (75%) | 20 (74%) | 22 (76%) |
| BMI, (kg/m2) | 24.2±6.6 | 25.1±8.1 | 23.4±5.0 |
| Body mass, (kg) | 68.0±17.8 | 68.7±19.8 | 67.4±16.2 |
| Lean mass of legs, (kg) | 16.2±4.1 | 16.3±4.1 | 16.2±16.1 |
| Tibia length, (cm) | 39.9±3.3 | 39.6±3.1 | 40.1±3.4 |
| Serum 25(OH)D, (ng/ml) | 17.5±8.7 | 17.1±9.3 | 17.9±9.3 |
Abbreviations: BMI, body mass index; cART, combination antiretroviral therapy; VitD3, vitamin D3; 25(OH)D, 25-hydroxyvitamin D; kg, kilogram; cm, centimeter. Data are mean ± SD or number (%). There were no significant differences between the placebo and VitD3 supplementation groups for any of the baseline covariates.